Background and aim: Spinal bulbar muscular atrophy (SBMA) is a progressive
Introduction
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy disease (KD), is a slowly progressive adult-onset X-linked neuromuscular disorder any effective treatments. It is characterized by limb and bulbar muscle wasting, weakness and fasciculation, associated with metabolic and endocrine alterations 1, 2 . SBMA is caused by the expansion of a CAG repeat in exon 1 of the androgen receptor (AR) gene; more than 37 repeats are pathogenic 1 .
There is a strong need for disease activity and progression markers, which are necessary for effective clinical trials. Furthermore, although the genetic test is diagnostic, there is a lack of biomarkers to aid the initial differential diagnosis of the disease. Neurofilaments (Nfs), both light and heavy chains, are now becoming a widely accepted prognostic biomarker for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases 3 . More than twenty years ago neurofilaments were first found to be increased in ALS CSF 4 . Reliable measurements of Nfs in peripheral biofluids have become available over the last five years, NfL were found to predict disease course in ALS and both NfL and pNfH are increased in a wide range of neurological conditions 3, 5, 6 . Nfs are currently being used as a biomarker in numerous clinical trials.
Recently, plasma NfL levels were found to be normal in SBMA patients 14 . This finding has supported other lines of evidence that point to a primary myopathic component in SBMA 2, 7, 8 .
We here investigated pNfH plasma levels in SBMA patients and in a wellestablished rodent model of disease, using the highly sensitive Simoa platform.
Materials and Methods

Study design
This is a cross-sectional study in which we enrolled SBMA and ALS patients, We also assessed the test in mice, 10 well-established mouse models of SBMA (AR100) and 10 wild type littermate controls.
Samples were processed, stored and analysed as previously described 5 . All blood samples were collected into EDTA-containing tubes, centrifuged at 20°C at 3.500 rpm for 10 minutes within 1 hour and stored at −80°C.
We measured pNfH levels in plasma performing a single molecule array (Simoa)-based assay (Quanterix, Lexington, MA) 9 , using pNF-Heavy Discovery Kit
102669.
Clinical assessment
SBMA patients had a genetical confirm of diagnosis, while ALS patients had a diagnosis of definite or probable ALS according to the revised El-Escorial criteria 10 . Disease severity was assessed using ALSFRSr
11
, SBMA FunctionalRating-Scale (SBMAFRS) 12 and Adult-Myositis-Assessment-Tool (AMAT) 13 scale in SBMA patients and using ALSFRS-r scale in ALS patients. Demographic and clinical data of patients are gathered in Table 1 .
Statistical analysis
Mann-Whitney U test and Kruskal-Wallis tests were performed to analyse plasma pNfH levels between groups. Dunn's multiple comparisons test was performed following Kruskal-Wallis test in case of significant differences. Receiver operating characteristic (ROC) curve, and the corresponding sensitivity, specificity, positive and negative predictive values, accompanied by their 95% CIs, was performed in order to identify the best cut-off level of pNfH to separate ALS and SBMA patients.
Correlation between parameters was calculated by Spearman rank correlation r.
The level of significance for all statistical tests was set at 0.05. The program Prism V.8 (GraphPad Software, La Jolla, CA) was used to perform statistical calculations.
Results
This study included 46 patients with SBMA, 50 ALS patients and 50 HCs.
Participant demographic and clinical characteristics are summarized in Table 1 .
We measured pNfH on plasma samples using a Simoa assay and found levels to be unchanged in SBMA vs HCs ( Figure 1A) . Of note, mean pNfH levels in SMBA were lower than HCs, although this difference was not statistically significant using Dunn's multiple comparison test. These results were also confirmed in SBMA mice, where pNfH levels were lower than WT mice (p= 0,009) ( Figure 1B) .
Conversely, in both fast-and slow-progressing ALS groups there was a statistically significant increase of plasma pNfH levels compared to HCs (ALSSlow p<0.001; ALS-Fast p<0.0001), conforming with previous reports 3, 5 . Importantly, pNfH plasma levels were significantly different between SBMA and both ALS groups (p<0.0001). In order to identify the pNfH threshold to most effectively distinguish SBMA from ALS, we created a ROC curve (AUC=0.95, p<0.0001; Figure 1D ) and defined pNfH of 105 pg/ml (highest Youden-Index) as the best cut-off between ALS and SBMA (98% sensitivity, 86% specificity). Given the similarity of results previously reported with NfL, we compared pNfH with previously measured NfL levels, in the same samples 14 . Cox regression model analysis, showed a significant correlation between pNfH and NfL levels (r s =0.77, p<0.0001; Figure 1C ).
Discussion
Contrary to what would be expected in a motor cell disorder 3, 14, 15 , this study shows low levels of pNfH in SBMA patients rather than a disease-related increase, as demonstrated in ALS and in primary lateral sclerosis. The result was also confirmed in a well-established SBMA mouse model.
We highlighted an increase of pNfH levels in ALS, and, beyond to what previously reported 15 , we have also found a correlation between pNfH levels and disease progression rate in ALS (calculated as PRL). As pNfH levels are increased in the initial phases of ALS 15 , this finding could be complementary to genetics to provide an early differential diagnosis for SBMA and other lower motor neuron diseases. It could also bear importance in predicting disease progression and in patient stratification for clinical trials.
We have also seen no relationships between pNfH levels and the stage of disease (quantified using functional and motor scales) both in SBMA and in ALS patients. This could suggest an absence of variation of pNfH levels during the course of these diseases, confirming previous data obtained in ALS with in-house ELISA test 15 .
Moreover, pNfH and NfL measurements in the same patients showed a good correlation; this correlation is tighter in ALS group than SBMA and HCs groups, due to the highest variability of measurement when detecting low levels of neurofilaments. Further work will be needed to assess whether combining these measurements could ameliorate the predictive value of the test.
Using ROC curve, we were also able to identify a statistically strong cut-off level (AUC=0.95) of pNfH that could distinguish SBMA from ALS. This suggests that pNfH could be used as a biomarker for the differential diagnosis between SBMA and ALS.
Limits of this study are represented by the cross-sectional design that does not allow us to infer about the variation of pNfH during the disease course. With regard to the analytical aspect, in this study we employed one of the most sensitive platforms for neurofilament analysis; this approach was the same used for the NfL study 14 . Unlike the measurement of NfL, previous work on the detection of plasma neurofilament isoforms has highlighted the inherent difficulties encountered in pNfH measuring in biological fluids, including the lack of linearity in dilution experiments and the presence of pNfH immunocomplexes or aggregates in circulation; that could cause epitope masking and make measurements for clinical stratification difficult 15 .
Finally, normal levels of pNfH in SBMA are in contrast not only with ALS, but also with previous findings on peripheral neuropathies 3, 5 , that share a slow disease course, although have a mild to moderate pNfH increase. Unfortunately, the latter data resulted from small cohorts of patients, included in largest studies, or from case reports and pNfH was measured using in-house ELISA test; so there could have been an underestimation of results.
This data supports the recent hypothesis of a primary muscle origin of damage in SBMA patients 2,4,13,14 and is consistent with results of NfL in SBMA 14 .
Under this light, it could be useful to measure, in a prospective study, pNfH levels in primary muscle atrophy and other pure lower motor neuron diseases, using Simoa platform.
Conclusions
In conclusion, we have demonstrated that plasma pNfH concentrations are not increased in SBMA patients and in a mouse model of disease, as opposed to ALS, and that pNfH could be used as a biomarker in differential diagnosis between SBMA and ALS. 
